Dose-limiting toxicity and maximum tolerated dose: still fit for purpose?-Reference-Cited by-同舟云学术

Dose-limiting toxicity and maximum tolerated dose: still fit for purpose?

Published:2015-10 Issue:13 Volume:16 Page:1287-1288
ISSN:1470-2045
Container-title:The Lancet Oncology
language:en
Short-container-title:The Lancet Oncology

Author:

Wong Han Hsi,Halford Sarah

Publisher

Elsevier BV

Subject

Oncology

Reference9 articles.

1. Phase I oncology studies: evidence that in the era of targeted therapies patients on lower doses do not fare worse;Jain;Clin Cancer Res,2010

2. Trends in the characteristics, dose-limiting toxicities and efficacy of phase I oncology trials: The Cancer Research UK experience;Wong;Proc Am Soc Clin Oncol,2015

3. Phase I trials of molecularly targeted agents: should we pay more attention to late toxicities?;Postel-Vinay;J Clin Oncol,2011

4. Defining dose-limiting toxicity for phase 1 trials of molecularly targeted agents: results of a DLT-TARGETT international survey;Paoletti;Eur J Cancer,2014

5. Phase II study of receptor-enhanced chemosensitivity using recombinant humanized anti-p185HER/neu monoclonal antibody plus cisplatin in patients with HER2/neu-overexpressing metastatic breast cancer refractory to chemotherapy treatment;Pegram;J Clin Oncol,1998

Cited by 19 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Universal CAR 2.0 to overcome current limitations in CAR therapy;Frontiers in Immunology;2024-06-19

2. Metronomic chemotherapy in cancer treatment: new wine in an old bottle;Theranostics;2024

3. Dual‑directional effect of vinorelbine combined with cisplatin or fluorouracil on tumor growth and metastasis in metronomic chemotherapy in breast cancer;International Journal of Oncology;2023-12-08

4. Reporting and impact of subsequent cycle toxicities in oncology phase I clinical trials;Clinical Trials;2023-11-14

5. Dose-limiting mucositis: friend or foe?;Supportive Care in Cancer;2023-10